Refine Biotech, a prominent player in the synthetic biology sector, has successfully closed a C-round financing round valued at $14.2 million. The investment was led by Xingxiang Capital with participation from Ruipeng Xiangyu Fund, signaling strong confidence in the company's growth trajectory. These new funds are earmarked for accelerating commercial expansion and constructing new, state-of-the-art production facilities to meet rising market demand.
A Dual-Technology Growth Engine
At the core of its strategy, Refine Biotech employs a dual-wheel drive model that synergizes advanced plant extraction with cutting-edge synthetic biology. This approach underpins its three primary product platforms: natural sweeteners, natural functional ingredients, and pharmaceutical excipients. The company leverages this unique combination to develop innovative and sustainable ingredients for a wide range of health-focused industries.
Expanding Production to Meet Global Demand
To support its global supply chain, the company has established a robust manufacturing network with three production bases across China. These facilities are strategically located in Yangling, Shaanxi; Chuzhou, Anhui; and Hohhot, Inner Mongolia. The ongoing construction of the Hohhot biomanufacturing base, with a planned phase-one investment of $42.7 million, marks a significant capacity expansion.
This integrated production system ensures end-to-end quality control and provides a flexible, efficient supply network to serve a global clientele. By leveraging the unique resources and industrial advantages of each region, Refine can optimize its operations. This strategic infrastructure is fundamental to the company's promise of delivering high-quality, stable, and reliable natural ingredients.
Leading the Charge in Sugar Alternatives
Refine Biotech has made significant strides in the natural sweetener market, achieving industrial-scale production of both Erythritol and Allulose. The company has rapidly become one of China's top four suppliers of Erythritol, demonstrating its competitive manufacturing capabilities. Following the recent regulatory approval of Allulose in China, Refine is well-positioned to lead with its cost-effective one-step fermentation technology.
Collaborative Innovation and Market Application
The company's key advantage lies in its ability to translate complex biotechnology into market-ready applications that solve direct consumer pain points. It provides clients with comprehensive solutions, from raw ingredient development to customized formula creation, helping them capture the health-conscious market. This model has attracted over 50 leading domestic and international partners, including notable brands like Swisse, Yili, and Genki Forest.
Future Outlook and Diversification
Looking ahead, Refine Biotech plans to further solidify its technological foundation while exploring new frontiers in health and wellness. The company is already making early-stage investments in an animal health platform, aiming to provide nutrition and protection products for large-scale feed and breeding enterprises. This strategic diversification signals a broader vision for applying its core competencies across the entire health ecosystem.
This latest round of funding serves as a crucial milestone, empowering Refine Biotech to enhance its research and development and expand its global footprint. CEO Wang Xiaoyun affirmed the company's commitment to using its dual-technology platform to deliver healthier and more sustainable solutions to the global food industry. The investment will fuel its mission to redefine natural ingredients and create long-term value for customers and society.